PNMA2 and glioblastoma: For example, as elucidated by Cui and colleagues, MA2 suppresses glioblastoma progression and prolongs lifespan of GSC-grafted animals, which suggests that m6A methylation could be a promising target for anti-glioblastoma therapy [58].